Literature DB >> 23325820

Evaluation of Epstein-Barr virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays.

Lotfi Bounaadja1, Jocelyne Piret, Nathalie Goyette, Guy Boivin.   

Abstract

Evaluation of candidate antiviral drugs against Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6), and HHV-8 is hampered by the lack of convenient laboratory assays. We developed real-time quantitative PCR assays performed on supernatants of lymphoma cell lines and determined the 50% inhibitory concentrations (IC50s) of nucleoside, nucleotide, and pyrophosphate analogues against these herpesviruses.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23325820      PMCID： PMC3666796          DOI： 10.1128/JCM.03234-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  20 in total

1.  Real-time PCR as a versatile tool for investigating the susceptibility of human herpesvirus 6 to antiviral agents.

Authors:  Muriel Macé; Chaysavanh Manichanh; Pascale Bonnafous; Stéphanie Précigout; David Boutolleau; Agnès Gautheret-Dejean; Henri Agut
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

2.  Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate.

Authors:  J Luka; B Kallin; G Klein
Journal:  Virology       Date:  1979-04-15       Impact factor: 3.616

Review 3.  Human herpesvirus 6: a clinical update.

Authors:  Danielle M Zerr
Journal:  Herpes       Date:  2006-05

4.  Susceptibility of human herpesvirus 6 to antiviral compounds by flow cytometry analysis.

Authors:  C Manichanh; P Grenot; A Gautheret-Dejean; P Debré; J M Huraux; H Agut
Journal:  Cytometry       Date:  2000-06-01

5.  Development of a real-time polymerase chain reaction assay for the diagnosis of human herpesvirus-6 infection and application to bone marrow transplant patients.

Authors:  Agnès Gautheret-Dejean; Chaysavanh Manichanh; Florence Thien-Ah-Koon; Anne-Marie Fillet; Nicole Mangeney; Michel Vidaud; Nathalie Dhedin; Jean-Paul Vernant; Henri Agut
Journal:  J Virol Methods       Date:  2002-02       Impact factor: 2.014

6.  Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infections.

Authors:  Karen Brengel-Pesce; Patrice Morand; Anne Schmuck; Marie-Josette Bourgeat; Marlyse Buisson; Gérard Barguès; Makhlouf Bouzid; Jean-Marie Seigneurin
Journal:  J Med Virol       Date:  2002-03       Impact factor: 2.327

7.  Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.

Authors:  D H Kedes; D Ganem
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

8.  Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines.

Authors:  T M Buttke; J A McCubrey; T C Owen
Journal:  J Immunol Methods       Date:  1993-01-04       Impact factor: 2.303

9.  Identification of human herpesvirus-6 as a causal agent for exanthem subitum.

Authors:  K Yamanishi; T Okuno; K Shiraki; M Takahashi; T Kondo; Y Asano; T Kurata
Journal:  Lancet       Date:  1988-05-14       Impact factor: 79.321

10.  Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate.

Authors:  Karl Y Hostetler
Journal:  Viruses       Date:  2010-09-30       Impact factor: 5.818
View more
  3 in total

1.  Calibration technologies for correct determination of Epstein-Barr Virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays.

Authors:  Francesco Broccolo; Paolo Lusso; Mauro Malnati
Journal:  J Clin Microbiol       Date:  2013-06       Impact factor: 5.948

2.  Reply to "Calibration technologies for correct determination of Epstein-Barr Virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays".

Authors:  Lotfi Bounaadja; Jocelyne Piret; Nathalie Goyette; Guy Boivin
Journal:  J Clin Microbiol       Date:  2013-06       Impact factor: 5.948

Review 3.  KSHV targeted therapy: an update on inhibitors of viral lytic replication.

Authors:  Natacha Coen; Sophie Duraffour; Robert Snoeck; Graciela Andrei
Journal:  Viruses       Date:  2014-11-24       Impact factor: 5.048
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.